The present invention relates to tricyclic compounds. In particular, the present invention is related to an inhibitor of one or more FGFR enzymes which is a compound of Formula II and to pharmaceutical compositions of the same that may be useful in the treatment of FGFR-associated diseases, such as cancer, myeoloproliferative diseases, and skeletal or chondrocyte disorders.